STOCK TITAN

Akebia Therapeut Stock Price, News & Analysis

AKBA Nasdaq

Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.

Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical leader developing innovative therapies for kidney disease, including FDA-approved Auryxia® and investigational oral HIF inhibitor Vafseo™. This page provides authorized updates on clinical developments, regulatory milestones, and strategic initiatives shaping renal care.

Access Akebia's official press releases covering phase 3 trial results, regulatory submissions, and commercial partnerships with dialysis providers. Investors will find timely updates on financial performance, including earnings calls and SEC filings related to anemia treatment innovations.

Our curated news collection helps stakeholders track progress in HIF biology applications and chronic kidney disease management. Bookmark this page for verified updates on product approvals, research collaborations, and market expansion strategies directly from Akebia Therapeutics.

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) has announced the granting of stock options to eight newly-hired employees as part of their inducement award program. The grants, made on March 31, 2025, total 73,325 shares of common stock with an exercise price of $1.92 per share, matching the closing price on the grant date.

The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
none
-
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced its upcoming participation at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston from April 10-13, 2025. The company will present two research posters:

1. A study on cardiovascular risk in patients with DD-CKD comparing Vadadustat vs Darbepoetin Alfa (Poster: G-284)

2. Research on Vadadustat's treatment of anemia comparing older vs younger patients with Dialysis-Dependent-CKD (Poster: G-285)

Dr. Wolfgang Winkelmayer will present the latter study during an oral presentation on April 10, 2025, at 4:00 pm. Attendees can visit Akebia at Booth #1121 in the Exhibit Hall.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) has announced the pricing of its underwritten public offering of 25,000,000 shares of common stock at $2.00 per share. The offering is expected to generate gross proceeds of $50.0 million before deducting underwriting costs and other expenses.

The company has granted underwriters a 30-day option to purchase up to 3,750,000 additional shares at the public offering price, less underwriting discounts. The offering is set to close on March 21, 2025, subject to customary conditions.

The offering is being managed by Leerink Partners and Piper Sandler & Co. as joint bookrunning managers, with BTIG, as lead manager and H.C. Wainwright & Co. as co-manager. The shares are being offered through a shelf registration statement filed with the SEC on September 3, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.17%
Tags
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) has announced the commencement of an underwritten public offering of common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price, less underwriting discounts and commissions.

The offering will be managed jointly by Leerink Partners and Piper Sandler & Co. as bookrunning managers. The shares are being offered through a shelf registration statement filed with the SEC on September 3, 2024, and declared effective on September 12, 2024.

The offering's final terms will be disclosed in a final prospectus supplement to be filed with the SEC. The completion, size, and terms of the offering are subject to market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.17%
Tags
-
Rhea-AI Summary

Akebia Therapeutics (AKBA) reported its Q4 and full-year 2024 financial results, highlighting the successful launch of Vafseo® (vadadustat) in January 2025. The company expects Q1 2025 Vafseo net product revenues of $10-$11 million.

Key financial metrics for Q4 2024 include:

  • Total revenues: $46.5M (down from $56.2M in Q4 2023)
  • Auryxia® net product revenues: $44.4M (down from $53.2M)
  • Net loss: $22.8M (compared to $0.6M net income in Q4 2023)
  • Cash position: $51.9M as of December 31, 2024

The company secured commercial supply contracts with dialysis organizations covering nearly 100% of U.S. dialysis patients. Over 500 prescribers have written prescriptions for Vafseo, averaging 8 prescriptions each. Akebia plans to initiate the Phase 3 VALOR trial for non-dialysis CKD patients in H2 2025 and expects current cash resources to fund operations for at least two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.44%
Tags
-
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) has scheduled the release of its fourth quarter and full year 2024 financial results on Thursday, March 13, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day to discuss the financial performance and recent business developments.

Investors and interested parties can access the conference call through a registration link, with recommended dial-in 15 minutes before the scheduled start time. A live webcast will be available through the Investors section of Akebia's website, with an online archive accessible afterward at ir.akebia.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
conferences earnings
Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) has granted stock options to two newly-hired employees as part of their employment inducement package. The grants, issued on February 28, 2025, total 13,525 shares of common stock with an exercise price of $1.85 per share, matching the closing price on the grant date.

The options are structured with a four-year vesting schedule, where 25% of shares vest after the first year, followed by quarterly vesting of the remaining 75%. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) and are subject to Akebia's inducement award program terms and conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
-
Rhea-AI Summary

Akebia Therapeutics (AKBA) has granted stock options to seven newly-hired employees as part of their employment inducement package. The options allow for the purchase of a total of 130,763 shares of Akebia's common stock at an exercise price of $2.24 per share, matching the closing price on January 31, 2025.

The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and falls under Akebia's inducement award program, complying with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
-
Rhea-AI Summary

Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.

Market research indicates strong physician interest, with 99% of nephrologists considering prescribing Vafseo and 75% planning to do so within 6 months. The company plans to expand Vafseo's label through a Phase 3 trial for non-dialysis CKD patients, starting mid-2025, targeting a potential billion-dollar market opportunity.

U.S. Renal Care has enrolled over 650 patients in the VOICE clinical trial. Akebia confirms its current cash resources will fund operations, including the U.S. launch and pipeline development, for at least two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
Rhea-AI Summary

Akebia Therapeutics (AKBA) has granted stock options to one newly-hired employee as part of their employment inducement package. The grant, issued on December 31, 2024, consists of options to purchase 3,000 shares of Akebia's common stock at an exercise price of $1.90 per share, matching the closing price on the grant date.

The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and are subject to Akebia's inducement award program terms. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none

FAQ

What is the current stock price of Akebia Therapeut (AKBA)?

The current stock price of Akebia Therapeut (AKBA) is $3.62 as of July 3, 2025.

What is the market cap of Akebia Therapeut (AKBA)?

The market cap of Akebia Therapeut (AKBA) is approximately 982.3M.
Akebia Therapeut

Nasdaq:AKBA

AKBA Rankings

AKBA Stock Data

982.26M
245.21M
4.45%
28.9%
6.82%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CAMBRIDGE